Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amber Tong
Senior Editor {Endpoints}
Interesting comment on Alzheimer's ... "Slow Go!"
https://endpts.com/eli-lillys-dan-skovronsky-on-oral-glp-1-slower-ramp-for-alzheimers-and-deals-on-underappreciated-assets/
BENZINGA
7:02 AM ET 11/28/2023
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (AVXL) with a Buy and maintains $54 price target.
Why are you attacking me, McM? I'm the one, along w/ kevin et al, claiming that Anavex does know its responsibilities and will report accordingly.
Focus on the FUDsters ...
That again is not true. If the Company is aware it will not release data by year end, it needs to state that. It can not continue to misinform the public if it knows it is not going to happen.
Continue to spread your false narrative, but the facts are with SEC filings, the Company needs to state the current status, even if it changed from its last PR.
If the Company issues a statement in SEC filings that it knows is not true, then it is liable for any action taken by any investor relying on that statement.
So, if Anavex knows, as of the filing date, it can't release the Rett data by year's end, then it needs to modify that previously issued statement. Since it did not, Anavex anticipates it will release the data by 12/31/2023!
Actually that is not true. Subsequent events and estimates are required to be updated to the company's best knowledge as of the filing date. That is why companies might delay announcements until after SEC docs are filed as the company is still analyzing the results at the time of filing.
So catdaddy's red line (see below) should reflect Anavex's current view on that release.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173305196
Well, mrp, if there were ever a Trojan horse from Anavex, today's cc is it!
SBSS, I've been wondering about that sequence: Why scheduled a Monday morning call after a holiday weekend, releasing the PR 30 minutes before the call? There is something more to this, but what, I don't know.
Investor, have you seen the PR yet?
Interesting comparison: MDGL is a non-revenue firm with MC of $3.861 Billion and AVXL is a zero revenue company, too, with a MC of $579 Million. Both have a potential new SOC in its field (MDGL in NASH disease and AVXL in AD and other CNS diseases), but the MC's are so stunningly different. Might it be due to which plays ball with Wall Street and which doesn't?
P.S. Also, MDGL's retained earnings deficit is ~10x larger than AVXL's.
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
https://www.anavex.com/post/anavex-life-sciences-to-announce-fiscal-2023-year-end-financial-results-on-monday-november-27-2023?mc_cid=a5824b7d7e&mc_eid=0688b12ec0
Tred, are you blocking the replies to his posts? That is what I have done for others.
Peace and Happy Thanksgiving to you and your family ... and to everyone else, too.
powerwalker
Why do you claim he hasn't spoken to the fda? Like the EMA news was kept quiet, Anavex might have had extensive discussions with the fda, but does not want to share. As noted by others, EMA time frame is not imminent.
Thanks, Jimbo. I believed in the science early on and I support Dr. M's approach of silence (as in "silence is golden") because I have experienced with great emotional & economic distress when too much is revealed about the company's strategy before it should be ... and the negative consequences thereof.
Peace, Jimbo,
powerwalker
Investor, will that move your projection to 100% if Anavex and Lundbeck tied the knot?
https://www.lundbeck.com/global/about-us#:~:text=Lundbeck%20is%20a%20Global%20Pharmaceutical,of%20pharmaceuticals%20across%20the%20world.
I love that first sentence, especially the word "tirelessly" ... hope it is true as we need more pharma companies who place the sufferers first [before profits] like Lundbeck ... and Anavex!
Pazzo, I think it will be Lundbeck, which is a member of the Consortium, as is Merck and Takeda.
rx, isn't the most significant part of today's PR is that Anavex is stating that the P2b/3 shows benefits that reduce the impact of dementia. If this weren't true, lawsuits will fly when results are disclosed ... no lawyer worth his/her salt would allow a client to state this, unless it is TRUE!! Clayton Parker would not let this out unless it is TRUE!!
Jimbo, I think TGD and staff are passing out the menus and asking people how they want their steaks and burgers with a sit-down date of New Year's Eve, at the latest.
P.S. The shorts get theirs: "Fried!!"
kevin, we do most assuredly!!
Red, I don't think TGD wants brick and mortar responsibilities. IMO, he wants to develop the drugs through approval and license them world-wide @ significant royalty %'s.
falconer, you should add UK, too. It is closely tied to Australia and would probably be tied to a TGA submission. Also, I think some Rett ped participants were in UK.
Peace,
powerwalker
Hello, Ladies and Gentlemen:
I have been out this AM and am now catching up on all of the posts and I'm surprised by the overall opinion that Anavex is only working with the EMA and foregoing the fda.
We know jack-sh*t about the process with the fda, much like, as of 6 o'clock this morning, we knew the same about EMA process.
Please wait patiently for TGD et al to release info on the fda status, however long it takes. We should know within less than six weeks.
🤞
Place each other on "ignore" and those that reply to the other's posts.
No 10-Q, only 10-K is filed for year end. Filing and cc will probably be same day with cc first.
Ruby, notice george did not claim "Great News," but only "news."
My guess is on Monday or Tuesday, Anavex will announce the day when the fiscal year end report will be released/filed and when the cc will be held, probably a week after the release.
Thanks, Foo, for that and your subsequent post on the matter.
Fiscal year ended on September 30th. I believe Anavex has 75 days to file its 10-K, which is December 14th.
Does anyone know if TGD is attending, virtual or otherwise?
Jefferies London Healthcare Conference
NOVEMBER 14-16 • LONDON, UK
IMO, no Rett data until after the 10-K is filed, hence after the fiscal year end cc. My thinking if they disclose Rett before then, Anavex will need to include a summary of it in the 10-K, which brings the SEC into the picture. Lawyers and accountants would prefer to wait on these big events until after periodic filings are made and state data is being analyzed. Then, release the data a week later.
That's easy ... unless you don't understand the word "tomorrow" on a Tuesday means "Wednesday!"
But it did not hit $5.75 on Wednesday ... as you stated it would.
No, you stated:
It didn't and you were wrong ... just admit it.
It did not hit $5.75 today, Ziggy!
DFRAI, it doesn't.
So, what are your thoughts, Investor?
If you recall, the shorts' attorneys did file a case in 2015-6 with a plaintiff who owned 100 shares. The lawsuit was thrown out because it was ... 💩💩💩!!!
Musing during a MoW route today:
1) If the Rett Excellence trial results are just that "Excellent," that BP's eyes are opened wider to the potential of small molecules and the validity of homeostasis, such that a low rumble will begin for one of them to buy-out Anavex, which would not maximize shareholder value in the long run? [BP is anxious to read the Rett numbers, too, as many are interested in small molecules and homeostasis.]
2) To minimize that threat, would Anavex then time the Rett release to a period slightly before the peer review paper on the Alzheimer's P2b/3 trail results, thus establishing a higher value for Anavex?
3) TGD has a problem if Alzheimer's peer review release goes into 2024, given his committed to release Rett this year.
IMO, the two are released within a week of each other in 2023 or Rett will be released mid-December if peer review is not forthcoming in 2023.